SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

Share Price is delayed by 15 minutes
Get Live Data
2.21    0.00 (0.00%)
Bid:
2.19
Ask:
2.21
Spread: 0.02 (0.913%)
Market Cap: $714.60m
RTW Live PriceLast checked at - London Stock Exchange

Intraday Rtw Biotech Share Chart

Monthly Valuation Update and Factsheet

14 Feb 2025 07:00

RNS Number : 0864X
RTW Biotech Opportunities Ltd
14 February 2025
 

LEI: 549300Q7EXQQH6KF7Z84

14 February 2025

RTW Biotech Opportunities Ltd

Monthly Valuation Update and Factsheet

+4.3% NAV movement for the month

RTW Biotech Opportunities Ltd (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 31 January 2025 (the "NAV") was US$632.8 million, or US$1.89 per ordinary share, +4.3% from the previous month.

The monthly factsheet is available on the Company's website:

 

https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/

 

 

For Further Information

RTW Investments, LP

+44 20 7959 6361

Woody Stileman, Managing Director, Business Development

Krisha McCune, Director, Investor Relations

biotechopportunities@rtwfunds.com

 

Cadarn Capital (PR & Communications / Distribution & IR Partner)

Lucy Clark (PR)

David Harris (Distribution)

 

 

Deutsche Numis (Joint Corporate Broker)

 

+44 79 8418 4461

Lucy@cadarncapital.com

+44 73 6888 3211

david@cadarncapital.com

 

+44 20 7260 1000

Freddie Barnfield

 

Nathan Brown

 

Euan Brown

 

 

BofA Securities (Joint Corporate Broker)

+44 20 7628 1000

Edward Peel

 

Alex Penney

 

 

Altum (Guernsey) Limited (previously named Elysium Fund Management Limited)

 

+44 14 8170 3100

 

Joanna Duquemin Nicolle, Director

 

 

Sadie Morrison, Director

 

 

Morgan Stanley Fund Services USA LLC

+1 914 225 8885

 

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

***********

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

***********

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCDXLFFELLEBBK
Date   Source Headline
30th Apr 20257:00 amRNSJade Biosciences merges with Aerovate Therapeutics
29th Apr 20257:00 amRNSTransaction in Own Shares
28th Apr 20257:00 amRNSTransaction in Own Shares
25th Apr 20257:00 amRNSTransaction in Own Shares
22nd Apr 20257:00 amRNSTransaction in Own Shares
17th Apr 20251:30 pmRNSAnnual Financial Report
16th Apr 20257:00 amRNSTransaction in Own Shares
14th Apr 20257:01 amRNSTransaction in Own Shares
14th Apr 20257:00 amRNSMonthly Valuation Update and Factsheet
10th Apr 202512:30 pmRNSDirector/PDMR Shareholding
10th Apr 20257:00 amRNSTransaction in Own Shares
9th Apr 20257:00 amRNSTransaction in Own Shares
7th Apr 20257:00 amRNSTransaction in Own Shares
3rd Apr 202512:30 pmRNSNew Investment in AIRNA
2nd Apr 20257:00 amRNSTransaction in Own Shares
1st Apr 20257:00 amRNSTotal Voting Rights
31st Mar 20257:00 amRNSAnnual Financial Report
28th Mar 20257:00 amRNSTransaction in Own Shares
26th Mar 20257:00 amRNSTransaction in Own Shares
21st Mar 20257:00 amRNSTransaction in Own Shares
20th Mar 20257:00 amRNSTransaction in Own Shares
14th Mar 20257:01 amRNSTransaction in Own Shares
14th Mar 20257:00 amRNSMonthly Valuation Update and Factsheet
13th Mar 20257:00 amRNSTransaction in Own Shares
10th Mar 20257:00 amRNSNotice of Annual Results
7th Mar 20257:00 amRNSTransaction in Own Shares
26th Feb 20257:00 amRNSRTW CIO increases position to 15%
25th Feb 20251:00 pmRNSMaterial purchase by CIO of the Investment Manager
17th Feb 20257:00 amRNSDirector/PDMR Shareholding
14th Feb 20257:00 amRNSMonthly Valuation Update and Factsheet
28th Jan 20257:00 amRNSMaterial Update from Portfolio Company
27th Jan 20257:00 amRNSKailera Reports Positive Data in Ph2 Obesity Trial
17th Jan 20257:01 amRNSNew Investment in Series A of Windward Bio
17th Jan 20257:00 amRNSAdditional Investment in Umoja Biopharma
15th Jan 20257:00 amRNSMonthly Valuation Update and Factsheet
14th Jan 20257:00 amRNSAdditional Investment in Numab Therapeutics
10th Jan 20257:00 amRNSNew Investment in Series A of Alesta Therapeutics
30th Dec 20247:00 amRNSCORXEL Announces Two Significant Transactions
20th Dec 202412:15 pmRNSNew Investment in Series A of Ottimo Pharma
13th Dec 20247:00 amRNSMonthly Valuation Update and Factsheet
10th Dec 202412:00 pmRNSHolding(s) in Company
10th Dec 20247:00 amRNSAppointment of Senior Independent Director
15th Nov 20247:00 amRNSCORXEL Announces Acceptance of NDA for Aficamten
14th Nov 20247:00 amRNSMonthly Valuation Update and Factsheet
1st Nov 20242:00 pmRNSNew Investment in Series C Round of Evommune, Inc.
1st Nov 20247:00 amRNSRTW Biotech Opportunities’ 5th Anniversary
14th Oct 20246:12 pmRNSMonthly Valuation Update and Factsheet Replacement
14th Oct 20247:00 amRNSMonthly Valuation Update and Factsheet
3rd Oct 20247:00 amRNSLaunch of Obesity Company Kailera Therapeutics
2nd Oct 20247:00 amRNSNew Investment in Aktis Oncology

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.